Featured News
View ASX Announcements here.
CFO and Company Secretary Appointment (ASX Announcement)
Mar 3rd, 2023
Melbourne, Australia; 3 March 2023: Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY) is pleased to announce the appointment of Mr Justin Cahill as Chief Financial Officer (CFO) and Company Secretary, following an extensive executive search process. Justin will commence in the role in early April 2023.
Read MoreInterim Report and Half-Year Financial Results - H1FY23 (ASX Announcement)
Feb 28th, 2023
Melbourne, Australia; 28 February 2023: Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY) today releases its interim report and half-year financial results for the period ended 31 December 2022 (H1 FY23).
Read MoreAppointment of Company Secretary (ASX Announcement)
Feb 1st, 2023
Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY) advises, in accordance with ASX Listing Rule 3.16.1, that Ms Tracy Weimar from Vistra Australia has been appointed as interim Company Secretary, effective today.
Read MoreDr Russell Basser appointed as non-executive director (ASX Announcement)
Jan 31st, 2023
The Board of Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY) is pleased to announce the appointment of Dr Russell Basser as an independent non-executive director, effective from 20 February 2023.
Dr Basser is a medical oncologist and former corporate executive with over 30 years of international medical and biopharmaceutical experience, including 21 years at CSL.
Dr Basser has substantial expertise in international drug and vaccine development, having held multiple senior executive roles whilst at CSL, including Senior Vice President (SVP) of Research and Development at CSL Seqirus; Chief Medical Officer at CSL Limited / CSL Behring; and SVP of Global Clinical Research and Development at CSL Behring / CSL Limited.
Read More